Combined characterization of a pituitary adenoma and a subcutaneous lipoma in a MEN1 patient with a whole gene deletion by D. Rusconi et al.
Cancer Genetics 204 (2011) 309e315Combined characterization of a pituitary adenoma
and a subcutaneous lipoma in a MEN1 patient with
a whole gene deletion
Daniela Rusconi a, Emanuele Valtorta a, Ornella Rodeschini a, Daniela Giardino a,
Iughetti Lorenzo b, Barbara Predieri b, Marco Losa c, Lidia Larizza a,d,
Palma Finelli a,e,*
a Laboratory of Medical Cytogenetics and Molecular Genetics, IRCCS Istituto Auxologico Italiano, Milan, Italy; bDepartment of
Pediatrics, Universita di Modena e Reggio Emilia, Modena, Italy; cDepartment of Neurosurgery, IRCCS Ospedale San
Raffaele, Milan, Italy; dDivision of Medical Genetics, San Paolo School of Medicine, Universita degli Studi di Milano, Milan,
Italy; eDepartment of Biology and Genetics for Medical Sciences, Universita degli Studi di Milano, Milan, ItalyReceived Septe
25, 2011; accepted
* Corresponding
E-mail address:
2210-7762/$ - see
doi:10.1016/j.canceMultiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant hereditary disorder
associated with mutations of the MEN1 gene, which is characterized by combined tumors of
the parathyroid glands, pancreatic islet cells, and the anterior pituitary. A significant number of
patients with the clinical features of MEN1, however, do not show MEN1 mutations upon direct
sequencing. We describe a young woman who fulfilled the clinical and biochemical criteria for
MEN1 syndrome, but DNA sequencing did not indicate any MEN1 mutations. She developed
a prolactin-secreting pituitary macroadenoma, primary hyperparathyroidism with parathyroid
hyperplasia, pancreatic lesions, and two subcutaneous lipomas. Array comparative genomic
hybridization (aCGH) analysis of peripheral blood DNA revealed a heterozygous germline
deletion at 11q13.1 that spanned at least 22.23 kilobases and contained the entire MEN1 gene.
Integrated aCGH and cytogenetic analyses of the adenoma and lipoma tissues revealed somatic
inactivation of the wild-type MEN1 allele by different routes: the second hit of MEN1 recessive
oncogenesis leading to adenoma implied a loss of heterozygosity, whereas a balanced translo-
cation deleting the wild-type MEN1 allele primed the lipoma development. These findings show
that aCGH is a valuable means of optimizing genetic testing in MEN1 patients which comple-
ments other technologic approaches to elucidating the pathologic mechanisms of MEN1 tumors.
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somal dominant monogenic disorder with 95% penetrance
that occurs in approximately 1/30,000 people and has an
equal gender distribution (1e3). It is characterized by the
development of parathyroid adenomas (90e97%), pituitary
adenomas (15e50%), and duodenal and/or pancreatic
neuroendocrine tumors (30e80%) (4,5). In addition to these
major lesions, patients may develop adrenal or thyroid
adenomas, bronchial or thymic carcinoid tumors, and (albeit
less frequently) various non-endocrine tumors such asmber 20, 2010; received in revised form March
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rgen.2011.03.006lipomas, angiofibromas, collagenomas, and leiomyomas
(6,7). The clinical diagnosis is based on the presence of at
least two of the three main MEN1-related tumors (8,9), and
there are reports of both sporadic (de novo) and familial
forms. Familial MEN1 is diagnosed in the setting of a MEN1
case and a first-degree relative with at least one of the main
MEN1-related tumors; sporadic MEN1 when there is no
family history of MEN1-related tumors (10).
TheMEN1 causative gene (11) has 10 exons and encodes
a 610 amino acid protein known as menin, a ubiquitously
expressed nuclear protein that interacts with a number of the
proteins (12,13) involved in transcriptional regulation,
genome stability, and cell division and proliferation (14,15).
MEN1 acts as a tumor suppressor in accordance with the
“two-hit” model of hereditary cancer postulated by Knudson:
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togenesis) and generally remains silent until the first tumor
develops; the second hit leads to clonal expansion as a result
of the somatic loss of the MEN1 wild-type allele in the cell
target of neoplastic transformation (9,16).
More than 450 MEN1 germline mutations have been
identified so far (http://www.hgmd.org) (14,17), mainly
spread throughout the coding region. Most of them (>80%)
are inactivating nonsense and frameshift mutations that lead
to the premature truncation of menin, whereas whole or
partial gene germline deletions are quite rare (1%) (14). Nine
of the reported deletions are intragenic, although a few
encompass several exons and have been detected by
various molecular genetic techniques [Southern blotting,
reverse-transcriptase polymerase chain reaction, gene dose
assays, and long-range polymerase chain reaction; reviewed
in (18)]. Only two patients have been found to be constitutive
carriers of a larger deletion involving neighboring genes by
means of a gene dosage assay and multiplex ligation-
dependent probe amplification (MLPA) (19,20).
MEN1 germline mutations are detected in about 68% of
cases with a clinical diagnosis of familial MEN1, as well as in
26% of sporadic cases (21e23). The reasons for this low
detection rate are the following: 1) gross deletions that are
not picked up by direct DNA sequencing; 2) the presence of
mutations in the non-coding regions of the gene, which are
not routinely examined; 3) false-negative findings due to
preferential allele amplification; and 4) locus heterogeneity.
We herein describe a female patient with the MEN1
syndrome who was negative for MEN1 mutations upon DNA
sequencing, although array comparative genomic hybridiza-
tion (aCGH) analysis showed that she carries an 11q13.1
germline deletion encompassing the entire MEN1 gene.
She first came to clinical attention because of a prolactin-
secreting pituitary macroadenoma and primary hyperpara-
thyroidism with parathyroid hyperplasia but, during the
follow-up, was found to have developed two subcutaneous
lipomas and pancreatic lesions compatible with multiple
localizations of a pancreatic neuroendocrine tumor.
Characterizing cryptic mutations in apparently mutation-
negative patients is important because of its potential
diagnostic value and the fact that it may help to improve
patient management. Our findings indicate that aCGH is
a useful means of identifying deletions that may be mis-
sed by conventional mutation analysis and can thus
contribute toward optimizing the MEN1 mutation detection
rate. Furthermore, integrating cytogenetic, FISH, and aCGH
studies of lipoma and adenoma tissues can reveal themultiple
routes underlying the “second hit” of MEN1 oncogenesis.Materials and methods
Clinical report
The proband is a 23-year-old woman born of unrelated
parents with no family history of endocrinopathy. Written
informed consent for the research investigation, which was
approved by the Ethical Clinical Research Committee of
Istituto Auxologico Italiano, was obtained from one of the
parents.She was diagnosed as having MEN1 syndrome at the age
of 11 years, when she showed slowed growth, no pubertal
development, and wide incomplete bitemporal hemianopia.
Magnetic resonance imaging (MRI) of the pituitary gland
revealed a pituitary macroadenoma with horizontal, antero-
posterior, and vertical diameters of 20, 19 and 24 mm,
respectively. The tumor compressed and displaced the optic
chiasm, but there were no signs of any extension into the
cavernous sinuses.
Laboratory tests showed marked hyperprolactinemia
(1800 ng/mL; normal values, 5e25 ng/mL), hypercalcemia,
growth hormone (GH) deficiency, and a low level of insulin-like
growth factor I (IGF-I). Treatment was started with the long-
acting dopamine agonist cabergoline, the dose of which was
gradually increased to 3 mg/week. Prolactin (PRL) levels
decreased to about 100 ng/mL and the visual field defect
normalized, but a repeat MRI showed only marginal shrinkage
of the top part of the tumor.
Thyroid and parathyroid ultrasonography revealed an
apparently homogeneous thyroid parenchyma, but also a
13  7-mm oval mass at the base of the right thyroid lobe
that was suspected of being a parathyroid lesion. The results
of adrenal and pancreas computed tomography (CT) were
negative.
Thyroid scintigraphy Technetium-99m-methoxyisobutyl-
isonitrile (MIBI) showed accumulation within the lower pole of
the right thyroid lobe, thus confirming the presence of
a parathyroid adenoma.
It was impossible to make a cytologic diagnosis on the
basis of the findings of thyroid fine needle aspiration because
the cell sample was inadequate, but high parathyroid
hormone (PTH) levels (>2,000 ng/mL) were found in the
liquid. Given the provisional diagnosis of primary hyper-
parathyroidism, the patient was clinically diagnosed as
having MEN1 syndrome, although mutation screening of
MEN1 exons 2e10 by means of denaturing gradient gel
electrophoresis and direct sequencing was negative.
Total parathyroidectomy with the autografting of a small
piece of parathyroid gland into the left forearm was per-
formed at another hospital. The pathologic diagnosis was
parathyroid hyperplasia.
Recombinant GH replacement therapy was considered
because the persistent GH deficit led to stunted growth, but it
was not started because of the presence of the pituitary
tumor, which was subsequently removed by means of trans-
sphenoidal surgery. After surgery, continuous treatment with
cabergoline normalized the patient’s PRL levels (20 ng/mL)
and, as MRI showed that the pituitary tumor had been almost
completely excised, GH replacement therapy was started.
During the next 2 years, PRL levels gradually increased to
65 ng/mL, and MRI showed that the pituitary mass was slowly
re-growingdespite the continuationof the cabergoline therapy.
With the agreement of the patient and her parents, no radiation
therapy was administered because of the fear of side effects,
but the tumor was closely monitored with the aim of reserving
the option of a second surgical procedure in the case of
compressive symptoms or excessive tumor growth.
Three years later, when the patient was 14 years old,
ultrasonography revealed a subcutaneous 3  3.1-cm lipoma
on the right thigh. This soon became larger, and another
lipoma was found on the front wall of the left hemithorax.
After surgical excision, the first lipoma was histologically
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the proliferation of collagen-forming spindle cells).
By the time the patient was 15 years old, spontaneous
puberty had still not occurred because of the persisting
hyperprolactinemia (PRL levels were about 100 ng/mL) or
the destruction of the normal pituitary gland. As another
thorough examination (including a total body CT scan and
duodeno-pancreatic echo-endoscopy) did not reveal the
presence of a neuroendocrine tumor, the patient was primed
with estrogens to induce pubertal changes and the devel-
opment of secondary sexual characteristics. At the end of
the priming period, oral estrogens/progestins were started
to treat secondary hypogonadism, and GH replacement
therapy was discontinued.
During the next 4 years, the patient experienced the
recurrence of mild hypercalcemia with borderline high PTH
levels, her PRL levels gradually increased to 180 ng/mL, and
the vertical diameter of the pituitary tumor increased to
18 mm. Another trans-sphenoidal surgical procedure was
performed for the purpose of partial debulking, but a small
portion of residual tumor remaining in contact with the optic
pathway precluded the use of gamma knife radiosurgery.
The patient refused fractionated radiotherapy, and she
continued taking cabergoline at a dose of 3 mg/week.
When the patient was 22 years old, abdominal CT revealed
the presence of small hypodense pancreatic lesions, sug-
gesting a pancreatic neuroendocrine tumor. Cytologic exam-
ination of a specimen taken from the largest lesion under
echo-endoscopic guidance (maximum diameter, w 1 cm)
confirmed the existence of a non-functioning neuroendocrine
tumor, and the patient was therefore treated subcutaneously
(s.c.) with Long-Action Octreotide Formulation (octreotide
LAR) 30 mg every 28 days.
At the time of the last follow-up examination, 1 year after
starting octreotide LAR, there was no change in the size of
the pancreatic masses, and no new lesions had appeared;
the pituitary tumor was slowly re-growing at the same
apparent speed as in previous years.
Conventional cytogenetics
The patient’s peripheral blood lymphocytes and the cells of
the first lipoma were cytogenetically analyzed using standard
methods. A post-surgical sample of fresh lipoma tissue was
immediately processed by means of direct and short-term
cultures after treatment with pronase-E (1 mg/mL at room
temperature for 15 minutes). The chromosomes were studied
using the QFQ banding technique, and the karyotype was
described in accordance with the ISCN (2009) (24).
Fluorescence in situ hybridization (FISH)
FISH for chromosomes 11 and 3 was performed on meta-
phases using whole-chromosome painting (WCP) according
to the manufacturer’s protocols (Abbott Molecular, Des
Plains, IL). To characterize the 11q breakpoint, two contig-
uous BAC clones (RP11-885P1 and RP11-548G17) located
in band 11q13.1 were selected using the UCSC Genome
Browser (http://www.genome.ucsc.edu/, released March
2006) and provided by Prof. M. Rocchi (University of Bari,
Italy). The BAC FISH experiments were performed using theprotocols of Lichter et al. (25) and Lichter and Cremer (26),
with minor modifications.aCGH
Genomic DNA was extracted from the proband’s blood
and adenoma tissue using the DNeasy Blood & Tissue Kit
(Qiagen, Hilden, Germany), as instructed by the manufac-
turer. Pooled DNA from the peripheral blood of 10 gender-
matched healthy donors (Promega, Madison, WI) was used
as a reference for the patient’s peripheral blood and
adenoma tissue DNA, and the DNA extracted from the
patient’s peripheral blood was then used as a second refer-
ence for the DNA extracted from the adenoma tissue.
Genomic DNA (3 mg) was hybridized to the 244K micro-
array (Agilent Technologies, Palo Alto, CA), which consisted
of approximately 236,000 60-mer oligonucleotide probes
covering the entire genome at an average spatial resolution
of about 30 kilobases (kb), and was processed according to
the manufacturer’s instructions. Dye emission was captured
by a dual-laser Agilent scanner, and the images were pro-
cessed using Agilent Feature Extraction software 9.1, and
analyzed with DNA Analytics 4.0 software. A log2 ratio plot
between the test and reference genomic DNA was assigned
in such a way that any aberrations in the test DNA copy
number at a particular locus were indicated by the deviation
of the plots from a modal value of 0, and the calls were
identified using the ADM-2 algorithm.
The text aberration summaries were analyzed to calculate
the medium log2 ratios of every copy number alteration, and
distinguish mosaic and non-mosaic alterations. The expected
log2 ratio cut-off values for non-mosaic heterozygous and
homozygous deletions are 1 and 4, respectively. The
expected log2 ratio cut-off values for non-mosaic duplications
and triplications are þ0.5 and þ1, respectively. Lower-
average log2 ratios identified cell mosaics: e.g., a log2 ratio
of 0.3 represented a cell mosaic of about 50% (50%
anomalous and normal cells), as demonstrated by dilution
experiments (not shown).Results
Constitutional molecular karyotype of the MEN1
patient
Array CGH analysis of genomic DNA extracted from the
patient’s peripheral blood showed a heterozygous deletion
on chromosome band 11q13.1 that spanned at least
22.23 kb (chr11:64320682-64342914 base pairs), and con-
tained all of the MEN1 gene and the 50 end of the adjacent
MAP4K2 gene (Figure 1). The centromeric breakpoint map-
ped to within a 3.7 kb region between probes A_14_P135243
(normal) and A_16_P02458082 (deleted) (Chr11:64,316,
924-64,320,682 bp, UCSC, hg18), whereas the distal
breakpoint mapped to within a 7.7 kb region between
probes A_16_P02458112 (deleted) and A_16_P19263781
(normal) (Chr11: 64,342,914-64,350,624 bp, UCSC, hg18).
Furthermore, the patient also carried three copy
number polymorphisms (CNPs): a deletion on 11q11
(chr11:55134486-55187341) and a duplication on 14q11.2
Figure 1 Array CGH detection of a MEN1 gene deletion. The
array profile concentrated on a 355 kb window within the
11q13.1 interval containing the MEN1 deletion, and scatter plot
analysis revealed a deletion in 11q13.1 (a horizontal shift to the
left of 0). Each point represents a single probe. The log2 ratio
was plotted for all of the oligonucleotide probes on the basis of
their chromosome positions. The figure shows the aberration
calls identified using the ADM-2 algorithm (color-shaded areas).
312 D. Rusconi et al.(chr14:19154992-19490689), both of which contained an
olfactory receptor cluster, and a duplication on chromosome
15q11.2 (chr15:18683110-20079994) (Supplementary
Figure S1).
No parental DNA was available for testing, although we
did not expect to find the MEN1 deletion because they were
both asymptomatic.
Pituitary adenoma characterization
The experiments were performed using two different refer-
ences: the first was pooled gender-matched DNA from
healthy controls, and the second was DNA extracted from
the patient’s peripheral blood to highlight tumor-specific
rearrangements without the background of the patient’s
constitutive copy number variants. As expected, aCGH
analysis of the adenoma tissue showed the germline deletion
on chromosome band 11q13.1 in both experiments, but the
log2 ratio signal of <1 indicated the presence of about0.5 copies against the two copies present in the reference DNA
(median log2 ratio between 2 and 4; Figure 2, A and B).
We also found that the CNP on 11q11 had the sameMEN1
log2 ratio profile shift to the left of 1 (median log2 ratio
between 2 and 4; see Supplementary Figures S1 A2 and
S1 A3), whereas the shift profile of the two CNPs located on
14q11.2 and 15q11.2 was not different from that of the
patient’s blood (seeSupplementaryFiguresS1B2andS1C2).
There were also gross copy number aberrations
(including the partial loss of 1p), losses of chromosomes 11,
17 18, and 22, as well as gains of chromosomes 1q, 5, 6, 9,
15, and X (Figure 3). In addition, aCGH analysis revealed
cytogenetic heterogeneity within the tumor. As shown in
Figure 3, each of the chromosomes or chromosomal regions
involved in the numerical aberrations showed a specific
vertical up or down shift in the log2 ratio profile, which indi-
cated the presence of subclones in quantitatively different
ratios. The prevalent chromosomal aberrations were the loss
of 1p12-1pter, the loss of chromosomes 11 and 17, and the
gains of chromosomes 6, 9, and 15, all of which indicate
a high percentage of affected cells (Supplementary
Figure S2).
Lipoma cytogenetics and FISH characterization
Cytogenetic investigation revealed a 46,XX,t(3;11)(p21;q13)
karyotype in all of the analyzed lipoma metaphases
(Figure 4A), whereas the patient’s constitutional karyotype
looked normal.
Specific WCP 11 and WCP 3 paints confirmed the recip-
rocal translocation t(3;11)(p21;q13) (Figure 4B), and FISH
analyses of tumor metaphases using chromosome 11q13.1-
specific BAC probes made it possible to characterize the 11q
translocation breakpoint. In particular, RP11-885P1 (which
contains the MEN1 gene) gave only one signal on the
normal chromosome 11, thus revealing the presence of
a concomitant deletion at the translocation breakpoint on the
der(11) chromosome (Figure 4C). RP11-548G17, which is
located contiguously distal to RP11-885P1, allowed the
translocation breakpoint to be mapped to 11q13.1, proximally
to its target region, as it gave a signal on chromosome
der(3) and the normal chromosome 11 (Figures 4, D and E).
After the FISH study, the karyotype could be defined as
46,XX,t(3;11)(p21;q13). ish der(3)t(3;11)(p21;q13.1)(wcp3þ,
wpc11þ,RP11-548G17þ),der(11)t(3;11)(p21;q13.1)(wpc3þ,
wpc11þ,RP11-548G17-,RP11-885P1-).
Using RP11-885P1 on the metaphase spreads of the
patient’s peripheral blood, FISH gave two identically intense
hybridization signals on chromosome 11 because the consti-
tutive approximately 22.23 kb deletion was too small to be
detected by means of BAC FISH.
Discussion
Array CGH analysis revealed a germline deletion of the entire
MEN1 gene in our patient with sporadic MEN1 syndrome,
who was negative for MEN1 mutations upon direct DNA
sequencing. The deletion (22.23 kb) may be longer at the
ends because of the 11 kb gaps between the flanking
oligonucleotides showing a normal hybridization signal and
those delimiting the deletion. Interestingly, both of the gap
Figure 2 MEN1 array profile of the pituitary adenoma DNA. The array profile concentrated on a 355 kb 11q13.1 interval containing
the MEN1 gene deletion, and scatter plot analysis revealed a deletion in 11q13.1 with a horizontal shift to the left of 1 (to a log ratio
between 2 and 4). (A) The 11q13 profile obtained using the patient’s peripheral blood DNA as reference. (B) The profile obtained
using pooled DNA from the peripheral blood of 10 healthy donors as reference.
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contain several Alu sequences belonging to the same
subfamily that has been described previously as mediating
the deletion in MEN1 patients (19).
Array CGH analysis of the pituitary adenoma revealed the
absence of MEN1 alleles in at least some tumor cells
because the median log2 ratio of between 2 and 4 indi-
cates the presence of about 0.5 copies, against the two
copies in the reference DNA. In addition, a CNP on 11q11
(which involves an olfactory receptor cluster) had the same
MEN1 profile shift (see Supplementary Figure 1A), but notFigure 3 Array CGH profile of the pituitary adenoma. The whole g
from the patient’s blood (green): the two profiles are superimposed in
from chromosome 1 to 22 within each chromosome. The log2 ratio wa
chromosome positions; the vertical bars indicate the separation of ththe two CNPs located on chromosomes 14 and 15 (see
Supplementary Figure 1, B and C). Moreover, in line with
previous CGH findings concerning MEN1 syndrome-related
pituitary tumors (27), aCGH showed that the entire chromo-
some 11 was lost in a large number of cells.
Loss of the wild-typeMEN1 allele can be driven by at least
three mechanisms: 1) the loss of a whole chromosome 11 as
a result of mitotic nondisjunction; 2) the loss of chromosome
11 followed by reduplication; and 3) mitotic recombination
proximal to the 11q11 olfactory receptor cluster. The
hypothesis that best fits our overall results is the loss of theenomic aCGH profile of pituitary adenoma DNA (red) and DNA
the bottom panel. The oligonucleotide probes are shown in order
s plotted for all of the oligonucleotide probes on the basis of their
e chromosomes.
Figure 4 Lipoma cytogenetics and FISH characterization. (A) Partial metaphases showing chromosomes 3 and 11 involved in the
translocation. (B) FISH with WCP 3 (green) and WCP 11 (red) on chromosomes 3 and 11. (C) BAC RP11-885P1 (11q13.1)
hybridization showing a signal on chromosome 11 (arrow) but not on the der(11) (arrowhead), thus confirming the presence of aMEN1
deletion associated with a targeted translocation event. (D) BAC RP11-548G17 (11q13.1) showing a signal on chromosome 11
(arrowhead) and der(3) (arrow) that targets the boundary of the 11q region translocated onto the chromosome der(3). (E) Physical
map of the chromosome 11q13.1 breakpoint of the t(11;3)(q13.1;p21). The genomic clones used for the FISH experiments are
indicated by a green line; the black lines show the region constitutively deleted in the patient; the known UCSC genes are shown in
blue. The scale refers to the March 2006 human draft sequence (hg18) from the UCSC genome browser (http://genome.ucsc.edu/
cgi-bin/hgGateway?orgZHuman).
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chromosome bearing the MEN1 deletion.
The cytogenetic heterogeneity in the tumor revealed by
aCGH analysis bears witness to clonal evolution, and the
additional large copy number aberrations correlate well with
previous aCGH and FISH findings (27e32). In particular, the
three chromosomal aberrations observed in a large number
of cells (the 1p12w1pter and chromosome 11 and 17 losses)
coincide with the most frequent cytogenetic changes identi-
fied in previous studies (27,28).
The aCGH findings indicate a hyperdiploid karyotype, but
do not correlate with the complex karyotype (56w79,XX,þX
[2],þ1[3],þ7[2],þ8[3],þ9[3],þ11[3],þ13[2],þ14[3],þ16[3],þ20
[3],þ22[2][cp3]; this suggests a near-triploid set, which has
been identified previously by karyotyping, although restricted
to only three metaphases (33).
Cytogenetic and FISH studies of the lipoma identified
a t(3;11)(p21;q13) and a concomitant deletion involving the
MEN1 gene at the translocation breakpoint on der(11). BAC
FISH did not reveal the small constitutive MEN1 deletion, butwe hypothesize that the chromosome 11 involved in the
translocation was the one carrying the wild-type MEN1 allele.
We could not characterize the 3p21 translocation break-
point by means of BAC FISH because of the lack of meta-
phases. The cytogenetic data so far collected in the Mitelman
Database of Chromosome Aberrations in Cancer (http://
www.cgap.nci.nih.gov/Chromosomes/Mitelman) show that
chromosome deletions on 3p are frequent in the majority of
solid tumors and many lymphoid malignancies. Moreover,
a number of studies have demonstrated that the 3p21 band
is highly prevalent in breakage-prone tumors (34), probably
because of its intrinsic fragility (35).
In conclusion, detecting gross deletions in theMEN1 gene
in apparently mutation-negative patients who are clinically
suspected of being affected by MEN1 is important because
of their potential diagnostic value and the contributions they
can make to clinical management.
The results of our combined cytogenetic, FISH, and
aCGH studies of the adenoma and lipoma tissues are
consistent with the MEN1 recessive oncogenesis model, and
Pituitary adenoma and lipoma due to germline MEN1 deletion 315highlight the multiple routes underlying the two hits of MEN1
oncogenesis.
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